Peter Barnes is a Senior Research Investigator at the National Heart and Lung Institute and Honorary Consultant Physician at Royal Brompton Hospital, London.
He qualified at Cambridge and Oxford Universities (first class honours) and was appointed to his present post in 1987. He has published over 1000 peer-review papers on asthma, COPD and related topics and has edited over 40 books (h-index = 153). He is also amongst the top 50 most highly cited researchers in the world and has been the most highly cited clinical scientist in the UK and the most highly cited respiratory researcher in the world over the last 20 years. He was elected a Fellow of the Royal Society in 2007, the first respiratory researcher for over 150 years. He has been a member of the Scientific Committee of global guidelines on asthma (GINA) and COPD (GOLD). He also serves on the Editorial Board of over 30 journals and is currently an Associate Editor of Chest, Journal of COPD Foundation, Respiratory Editor of PLoS Medicine and Editor in Chief of Up-to-Date Pulmonary Diseases. He has given several prestigious lectures, including the Amberson Lecture at the American Thoracic Society, the Sadoul Lecture at the European Respiratory Society and the Croonian Lecture at the Royal College of Physicians. He has received honorary MD degrees from the Universities of Ferrara (Italy), Athens (Greece), Tampere (Finland) and Leuven (Belgium). He is an Emeritus NIHR Senior Investigator,a Master Fellow of the American College of Chest Physicians and a member of the Academia Europaea. He was President of the European Respiratory Society 2013/14. He co-founded an Imperial spin-out company RespiVert, which was acquired by Johnson & Johnson and has developed novel inhaled treatments for COPD and severe asthma.
His research is focused on cellular and molecular mechanisms of asthma and COPD, understanding and developing therapies and research into biomarkers for these diseases. He is involved in multidisciplinary translational research which integrates basic science with clinical studies, thereby providing novel insights into common airway diseases.
et al., 2021, IL36 is a critical upstream amplifier of neutrophilic lung inflammation in mice, Communications Biology, Vol:4, ISSN:2399-3642, Pages:1-15
et al., 2021, Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial, Lancet, Vol:398, ISSN:0140-6736, Pages:843-855
et al., 2021, The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease., Lancet Respir Med
et al., 2021, Case Report: Ketogenic Diet Is Associated With Improvements in Chronic Obstructive Pulmonary Disease, Frontiers in Medicine, Vol:8
et al., 2021, Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma, International Conference of the American-Thoracic-Society, ELSEVIER, Pages:3069-+, ISSN:2213-2198